Another cancer injectable drug goes into shortage

(By Paige Twenter for Becker’s Hospital Review)

Multiple solutions of etoposide, an injectable used for testicular and small cell lung cancer, are on back order until spring.

Three solutions from Accord Healthcare, two from Hikma Pharmaceuticals and one from Fresenius Kabi are in shortage, according to a drug supply database run by the American Society of Health-System Pharmacists. In 2022, Teva Pharmaceuticals stopped marketing the product. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.